Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
about
A novel Respiratory Health Score (RHS) supports a role of acute lung damage and pig breed in the course of an Actinobacillus pleuropneumoniae infectionA new variant of Actinobacillus pleuropneumoniae serotype 3 lacking the entire apxII operon.Draft genome sequences of Actinobacillus pleuropneumoniae serotypes 2 and 6.Experimental Actinobacillus pleuropneumoniae challenge in swine: comparison of computed tomographic and radiographic findings during disease.Actinobacillus pleuropneumoniae challenge in swine: diagnostic of lung alterations by infrared thermography.PR-39, a porcine host defence peptide, is prominent in mucosa and lymphatic tissue of the respiratory tract in healthy pigs and pigs infected with Actinobacillus pleuropneumoniaeThe generation of successive unmarked mutations and chromosomal insertion of heterologous genes in Actinobacillus pleuropneumoniae using natural transformationAttenuated Actinobacillus pleuropneumoniae double-deletion mutant S-8∆clpP/apxIIC confers protection against homologous or heterologous strain challenge.Immunoprotective Efficacy of Six In vivo-Induced Antigens against Actinobacillus pleuropneumoniae as Potential Vaccine Candidates in Murine ModelPathway deregulation and expression QTLs in response to Actinobacillus pleuropneumoniae infection in swine.Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.Proteomic and immunoproteomic characterization of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae.Construction and immunogenicity of a ∆apxIC/ompP2 mutant of Actinobacillus pleuropneumoniae and Haemophilus parasuis.Update on Actinobacillus pleuropneumoniae-knowledge, gaps and challenges.Treatment of infected lungs by ex vivo perfusion with high dose antibiotics and autotransplantation: A pilot study in pigs.
P2860
Q33433182-D6625F83-C024-4E0C-8E1B-646663DEEA18Q34015934-B1F6F2C2-992B-4B4E-996D-1483FA582CFFQ34192706-4C454BC5-4360-412C-A823-827DC8F1D799Q34251999-D98AC59F-26B8-4266-8887-8C507E4BEF8AQ34267372-35200119-944B-4964-9FB5-92F936CDE2F9Q34422878-E5D367B3-CA11-4C51-9E3A-859044930EE6Q35435748-EB2E75CB-B631-4268-A9A7-AE7075522302Q36243182-20E2DC96-C8EB-48C5-BD02-0BCAD06646C3Q37356033-45761732-77BA-4F41-B4F6-5DBECC58F07DQ38473920-2A1B82C9-4269-4031-BBFA-53931472B06CQ40594193-721BAA71-4FD1-4E6A-987D-73BAAD92BE21Q42745711-4F41CCFE-2EDD-4C8F-AEA2-202E2FF7662AQ44651886-59B2E5CC-67F3-4ED8-A71D-164B6E3C7AA7Q47728701-2C4B4C09-95C9-4164-AF42-27A2A2280114Q52673973-5530A75F-07F3-406C-A9FC-D0D21E3F1817
P2860
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@ast
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@en
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@nl
type
label
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@ast
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@en
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@nl
prefLabel
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@ast
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@en
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@nl
P2093
P1433
P1476
Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
@en
P2093
Alexander Maas
Gerald-F Gerlach
Isabel Hennig-Pauka
Jochen Meens
Nina Baltes
P304
P356
10.1016/J.VACCINE.2006.06.047
P407
P577
2006-07-07T00:00:00Z